MindUp BioResearch (HIRU) Research Team Published Their New Results on the Topic of Overcoming Multiple-Drug Resistance in Lu...
August 04 2011 - 3:45PM
Marketwired
Hiru Corporation (PINK SHEETS: HIRU)
(http://www.hirucorporation.com/), is pleased to announce that
researchers from its MindUp BioResearch
(www.mindupbioresearch.com), European subsidiary have published
their new results of preclinical studies on the topic of overcoming
multidrug resistance, a frequent phenomenon occurring in cancer
that seriously limit the efficacy of lung cancer course of therapy
with chemotherapeutic agents.
Dr Sabera Ruzdijic, the Leader of MindUp Bioresearch Group said:
"In this paper we examined the effect of two purine analogs
sulfinosine (SF) and 8-Cl-cAMP on cell growth inhibition in
parental and resistant human lung carcinoma cell lines.
Pretreatment with purine analogues was more potent in improving the
sensitivity of resistant lung carcinoma cells to doxorubicin than
conventional chemo-sensitizing agent - verapamil (VER).
Combinations of either SF or 8-Cl-cAMP with VER at clinically
acceptable concentrations exhibited synergistic effects on cell
growth inhibition in the resistant lung carcinoma cell line.
Together with their ability to reverse multidrug resistance, these
results render the purine analogs (in combination with VER) as
potential candidates for improving the clinical activity of
existing lung cancer therapeutics.
Dr Sabera Ruzdijic added: "We are proud that these results are
accepted and published in the prestigious journal Investigational
New Drugs (2010) 28:482-492 by Pesic et al.
(http://www.springerlink.com/content/w2h2805230314332/)". At the
company website http://www.hirucorporation.com/ you can find the
PDF of article.
In other company news and updates, MindUp division is currently
in negotiation discussions as a buyout candidate. The management is
of the opinion that this is a material event that warrants a news
release.
More details will follow on the MindUp divestiture as it becomes
available.
Safe Harbor Statement
Information in this news release may contain statements about
future expectations, plans, prospects or performance of Hiru
Corporation that constitute forward-looking statements for purposes
of the Safe Harbor Provisions under the Private Securities
Litigation Reform Act of 1995. The words or phrases "can be",
"expects", "may affect", "believed", "estimate", "project" and
similar words and phrases are intended to identify such
forward-looking statements. Hiru Corporation cautions you that any
forward-looking information provided by or on behalf of Hiru
Corporation is not a guarantee of future performance. None of the
information in this press release constitutes or is intended as an
offer to sell securities or investment advice of any kind. Hiru
Corporation's actual results may differ materially from those
anticipated in such forward-looking statements as a result of
various important factors, some of which are beyond Hiru
Corporation's control. In addition to those discussed in Hiru
Corporation's press releases, public filings, and statements by
Hiru Corporation's management, including, but not limited to, Hiru
Corporation's estimate of the sufficiency of its existing capital
resources, Hiru Corporation's ability to raise additional capital
to fund future operations, Hiru Corporation's ability to repay its
existing indebtedness, the uncertainties involved in estimating
market opportunities, and in identifying contracts which match Hiru
Corporation's capability to be awarded contracts. All such
forward-looking statements are current only as of the date on which
such statements were made. Hiru Corporation does not undertake any
obligation to publicly update any forward-looking statement to
reflect events or circumstances after the date on which any such
statement is made or to reflect the occurrence of unanticipated
events.
Contacts: Hiru Corporation corporate@hirucorporation.com
Hiru (PK) (USOTC:HIRU)
Historical Stock Chart
From Nov 2024 to Dec 2024
Hiru (PK) (USOTC:HIRU)
Historical Stock Chart
From Dec 2023 to Dec 2024